TW202337410A - Contact lens product - Google Patents

Abstract

A contact lens product includes a contact lens and a buffer solution. The contact lens is stored in the buffer solution. The buffer solution includes at least one antioxidant. The contact lens includes at least one curcuminoid. Therefore, it is favorable for the contact lens to effectively absorb high-energy UV light or blue light of the environment and convert into weak-energy light, so that the retina can be protected and the damages thereon can be reduced effectively.

Description

contact lens products

The present invention relates to a contact lens product, in particular to a contact lens product that helps reduce stray light and eliminate glare.

In order to protect the eyes from strong light damage, general contact lenses use traditional technology to use chemically synthesized UV/blue light absorbers to achieve a blocking effect. However, traditional light absorbers can easily cause discomfort when they come into contact with the eyes, and excessive doses may even cause Causes serious eye immune reaction or toxic damage, but generally curcumin (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione ) cannot have a good bonding effect with the contact lens monomer, causing it to be easily released from the contact lens, and may even be unable to overcome the high temperature and high pressure sterilization process and cause decomposition.

According to the present invention, a contact lens product is provided, which includes a contact lens and a buffer solution. The contact lens is stored in a buffer solution, wherein the buffer solution contains at least one antioxidant. The contact lens contains at least one curcumin derivative, and the curcumin derivative has a structure represented by formula (I) or formula (II): Formula (I), wherein R ₁ and R ₂ are not both hydrogen; or Formula (II), Wherein R ₅ is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid and 2-methyl-2-acrylic acid-2,3-dihydroxypropyl ester, and R ₃ and R ₄ are not hydrogen at the same time. . The weight percentage concentration of the curcumin derivative in the contact lens is Ccu, and the weight percentage concentration of the antioxidant in the buffer solution is Cao, which satisfies the following conditions: 0.01% ≤ Ccu ≤ 5.00%; and 0.05% ≤ Cao ≤ 5.00%.

Therefore, the contact lens product of the present invention is designed to include a novel curcumin derivative with high monomer bonding efficiency obtained by modifying natural curcumin, and the curcumin derivative of the present invention has the effect of absorbing light and quickly changing color. , helps to efficiently absorb environmental high-energy ultraviolet light or blue light and convert it into low-energy light, which can effectively protect the retina and reduce damage. Furthermore, the contact lens product of the present invention is further designed to have an appropriate concentration of antioxidants to overcome the problem of the contact lens product destroying the stability of the curcumin derivative due to high temperature and high pressure sterilization, and the optimal antioxidant concentration in the buffer solution The combination can effectively stabilize and prolong the absorption effect of the curcumin derivative of the present invention, so as to fully exert the anti-glare protection effect of contact lenses.

Please refer to FIG. 1 , which is a schematic diagram of a contact lens product 100 according to an embodiment of the present invention. The contact lens product 100 includes a contact lens 110 and a buffer solution 120 . The contact lens 110 is stored in a buffer solution 120, and the buffer solution 120 contains at least one antioxidant.

The contact lens 110 includes at least one curcumin derivative (Curcuminoid), and the curcumin derivative has a structure shown in Formula (I) or Formula (II): Formula (I), Wherein at least one of R ₁ and R ₂ is selected from hydroxyethyl methacrylate (2-Hydroxyethyl methacrylate, HEMA), methacrylic acid (Methacrylic Acid, MAA), 2-methyl-2-acrylic acid-2,3 - A group consisting of Glycerol monomethacrylate (GMA) and hydrogen (H), and R ₁ and R ₂ are not hydrogen at the same time; or Formula (II), Wherein at least one of R ₃ and R ₄ is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid, 2-methyl-2-acrylate-2,3-dihydroxypropyl ester and hydrogen, R ₅ is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid and 2-methyl-2-acrylic acid-2,3-dihydroxypropyl ester, and R ₃ and R ₄ are not hydrogen at the same time.

In the contact lens product 100 of the present invention, the weight percent concentration of the curcumin derivative in the contact lens 110 is Ccu, and the weight percent concentration of the antioxidant in the buffer solution 120 is Cao, which satisfies the following conditions: 0.01 ≤ Ccu/Cao ≤ 10.00. Alternatively, it can satisfy the following conditions: 0.02 ≤ Ccu/Cao ≤ 8.00. Alternatively, it can satisfy the following conditions: 0.03 ≤ Ccu/Cao ≤ 3.00. Alternatively, it can satisfy the following conditions: 0.04 ≤ Ccu/Cao ≤ 1.00. Alternatively, it can satisfy the following conditions: 0.05 ≤ Ccu/Cao ≤ 0.70.

Thereby, the contact lens 110 of the contact lens product 100 of the present invention is designed to include at least one novel curcumin derivative with high monomer bonding efficiency obtained by modifying natural curcumin, and the curcumin derivative of the present invention has The effect of absorbing light and quickly changing color helps to efficiently absorb environmental high-energy ultraviolet or blue light and convert it into low-energy light, which can effectively protect the retina and reduce damage. Furthermore, the contact lens product 100 of the present invention is further designed to have an appropriate concentration of antioxidants to overcome the problem of the contact lens product 100 destroying the stability of the curcumin derivative due to high temperature and high pressure sterilization, and the optimal antioxidant in the buffer solution 120 The combination of oxide concentrations can effectively stabilize and prolong the absorption effect of the curcumin derivative of the present invention, so as to fully exert the anti-glare protection effect of the contact lens 110. Furthermore, the curcumin derivative of the contact lens 110 of the present invention can also be mixed with colorants to achieve the desired color change, and then be applied to multifocal contact lenses with vision slowing and vision control functions, so that it can help reduce stray light. To eliminate the effect of glare, and adjust the appropriate concentration to block strong light to achieve an efficient shading effect, but the invention is not limited to this.

In the contact lens product 100 of the present invention, at least one of R ₁ and R ₂ of the curcumin derivative of formula (I) can be hydroxyethyl methacrylate, and R ₃ of the curcumin derivative of formula (II) can be At least one of R ₄ may be hydroxyethyl methacrylate. In this way, the compatibility of the curcumin derivative during the production of the contact lens 110 can be increased, so that the monomer material can be directly bonded to the curcumin derivative and has good monomer bonding efficiency.

In the contact lens product 100 of the present invention, R ₅ of the curcumin derivative of formula (II) may be methacrylic acid or 2-methyl-2-acrylic acid-2,3-dihydroxypropyl ester. This can achieve better monomer bonding efficiency and help improve the bonding compatibility between curcumin derivatives and monomer materials.

In the contact lens product 100 of the present invention, the weight percent concentration of the curcumin derivative in the contact lens 110 is Ccu, which can meet the following conditions: 0.01% ≤ Ccu ≤ 5.00%. Thereby, the high-energy wavelength absorption effect of the contact lens 110 containing the curcumin derivative of the present invention can be effectively prolonged. Alternatively, it can satisfy the following conditions: 0.02% ≤ Ccu ≤ 4.00%. Alternatively, it can satisfy the following conditions: 0.03% ≤ Ccu ≤ 3.00%. Alternatively, it can satisfy the following conditions: 0.04% ≤ Ccu ≤ 2.00%. Alternatively, it can satisfy the following conditions: 0.04% ≤ Ccu ≤ 1.00%.

In the contact lens product 100 of the present invention, the weight percentage concentration of the antioxidant in the buffer solution 120 is Cao, which can meet the following conditions: 0.05% ≤ Cao ≤ 5.00%. Thereby, the high-energy wavelength absorption effect of the contact lens 110 containing the curcumin derivative of the present invention can be effectively prolonged. Alternatively, it can satisfy the following conditions: 0.06% ≤ Cao ≤ 4.00%. Alternatively, it can satisfy the following conditions: 0.07% ≤ Cao ≤ 3.00%. Alternatively, it can satisfy the following conditions: 0.08% ≤ Cao ≤ 2.00%. Alternatively, it can satisfy the following conditions: 0.09% ≤ Cao ≤ 1.50%.

In the contact lens product 100 of the present invention, the buffer solution 120 may further include at least one wetting agent. The wetting agent is configured in the buffer solution 120. The concentration of the wetting agent in weight percentage is Cad, and the concentration is defined as any The weight percent concentration of wetting agent that satisfies the following conditions: 0.001% ≤ Cad ≤ 1.00%. Thereby, the moisturizing and lubricating effects of the contact lens 110 can be effectively provided. Alternatively, it can satisfy the following conditions: 0.01% ≤ Cad ≤ 0.50%.

In the contact lens product 100 of the present invention, the molecular weight of the curcumin derivative is Wmc, which can satisfy the following conditions: 400 ≤ Wmc ≤ 800. In this way, through the optimal structural combination of curcumin derivatives, the absorption effect of curcumin derivatives can be maintained and the monomer bonding efficiency can be improved. Alternatively, it can satisfy the following conditions: 410 ≤ Wmc ≤ 750. Alternatively, it can satisfy the following conditions: 420 ≤ Wmc ≤ 700. Alternatively, it can satisfy the following conditions: 430 ≤ Wmc ≤ 600. Alternatively, it can satisfy the following conditions: 450 ≤ Wmc ≤ 500.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the average transmittance of the contact lens 110 at a wavelength of 280 nm~310 nm is T2831, which can meet the following conditions: 50% ≤ T2831 ≤ 90%. Thereby, appropriately adjusting the usage amount of the curcumin derivative can effectively improve the absorption effect of the contact lens 110 in the UVB range. Alternatively, it can satisfy the following conditions: 60% ≤ T2831 ≤ 88%. Alternatively, it can satisfy the following conditions: 70% ≤ T2831 ≤ 86%. Alternatively, it can satisfy the following conditions: 72% ≤ T2831 ≤ 80%.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the average transmittance of the contact lens 110 at a wavelength of 310 nm~380 nm is T3138, which can meet the following conditions: 60% ≤ T3138 ≤ 92%. Thereby, appropriately adjusting the usage amount of the curcumin derivative can effectively improve the absorption effect of the contact lens 110 in the UVA range. Alternatively, it can satisfy the following conditions: 60% ≤ T3138 ≤ 85%. Alternatively, it can satisfy the following conditions: 75% ≤ T3138 ≤ 85%.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the average transmittance of the contact lens 110 at wavelengths 410 nm to 460 nm is T4146, which can meet the following conditions: 70% ≤ T4146 ≤ 90%. Thereby, appropriately adjusting the usage amount of the curcumin derivative can effectively improve the absorption effect of the contact lens 110 in the blue light range. Alternatively, it can satisfy the following conditions: 75% ≤ T4146 ≤ 85%. Alternatively, it can satisfy the following conditions: 80% ≤ T4146 ≤ 90%.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the average transmittance of the contact lens 110 at a wavelength of 460 nm~780 nm is T4678, which can meet the following conditions: 90% ≤ T4678 ≤ 98%. Thereby, by appropriately adjusting the usage amount of the curcumin derivative, the high light transmittance effect of the contact lens 110 can be effectively maintained.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the average transmittance of the contact lens 110 at a wavelength of 380 nm~780 nm is T3878, which can meet the following conditions: 85% ≤ T3878 ≤ 98%. Thereby, by appropriately adjusting the usage amount of the curcumin derivative, the absorption and high light transmittance effects of the curcumin derivative of the contact lens 110 can be effectively balanced.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the absorption blocking efficiency of the contact lens 110 at a wavelength of 280 nm~310 nm is BE2831, which can meet the following conditions: 4.0% ≤ BE2831 ≤ 50.0 %. Thereby, the high-energy UVB light absorption effect of the contact lens 110 can be effectively maintained. Alternatively, it can satisfy the following conditions: 5.0% ≤ BE2831 ≤ 50.0%. Alternatively, it can satisfy the following conditions: 5.0% ≤ BE2831 ≤ 40.0%. Alternatively, it can satisfy the following conditions: 6.0% ≤ BE2831 ≤ 30.0%. Alternatively, it can satisfy the following conditions: 7.5% ≤ BE2831 ≤ 20.0%. Alternatively, it can satisfy the following conditions: 10.0% ≤ BE2831 ≤ 50.0%.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the absorption blocking efficiency of the contact lens 110 at a wavelength of 310 nm to 380 nm is BE3138, which can meet the following conditions: 3.0% ≤ BE3138 ≤ 35.0 %. Thereby, the high-energy UVA light absorption effect of the contact lens 110 can be effectively maintained. Alternatively, it can satisfy the following conditions: 3.5% ≤ BE3138 ≤ 30.0%. Alternatively, it can satisfy the following conditions: 5.0% ≤ BE3138 ≤ 35.0%. Alternatively, it can satisfy the following conditions: 7.5% ≤ BE3138 ≤ 35.0%. Alternatively, it can satisfy the following conditions: 10.0% ≤ BE3138 ≤ 20.0%.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the absorption blocking efficiency of the contact lens 110 at a wavelength of 410 nm~460 nm is BE4146, which can meet the following conditions: 1.0% ≤ BE4146 ≤ 30.0 %. Thereby, the high-energy blue light absorption effect of the contact lens 110 can be effectively maintained. Alternatively, it can satisfy the following conditions: 1.5% ≤ BE4146 ≤ 27.0%. Alternatively, it can satisfy the following conditions: 2.0% ≤ BE4146 ≤ 25.0%. Alternatively, it can satisfy the following conditions: 2.5% ≤ BE4146 ≤ 23.0%. Alternatively, it can satisfy the following conditions: 5.0% ≤ BE4146 ≤ 20.0%.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the absorption blocking efficiency of the contact lens 110 at a wavelength of 460 nm~780 nm is BE4678, which can meet the following conditions: 0.5% ≤ BE4678 ≤ 5.0 %. Thereby, the high light transmittance effect of the contact lens 110 can be effectively maintained.

In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the absorption blocking efficiency of the contact lens 110 at a wavelength of 380 nm to 780 nm is BE3878, which can meet the following conditions: 1.0% ≤ BE3878 ≤ 10.0 %. Thereby, the absorption and high light transmittance effects of the curcumin derivative of the contact lens 110 can be effectively balanced.

In the contact lens product 100 of the present invention, the contact lens 110 may include at least two curcumin derivatives. Thereby, the curcumin derivatives can be adjusted and selected according to the desired discoloration effect, and a mixture of multiple curcumin derivatives can achieve different color change performances.

In the contact lens product 100 of the present invention, the contact lens 110 may further include at least one color material. Thereby, the discoloration zone of the contact lens 110 of the present invention can contain a mixed color material of curcumin derivatives, so that the discoloration zone can achieve different color changes as required. If the discoloration zone is designed to be smaller than the ring shape of the optical zone, there will be Helps reduce stray light, allowing it to eliminate glare when used in multifocal contact lenses that slow and control vision. Alternatively, if the color-changing area is designed to be disc-shaped and cover the optical area, it can block strong light to achieve a light-reducing effect like sunglasses. Alternatively, if the discoloration area is further designed outside the non-optical area, the appearance of the contact lens 110 can be adjusted to achieve the effect of enlarging the iris.

Furthermore, in the contact lens product 100 of the present invention, the color material of the contact lens 110 can form a pattern. Patterns can contain text, numbers or patterns, and can have directional and representative functions, and can produce identification marks, expiry date instructions, direction identification, indicating possible environmental hazards, etc.

In the contact lens product 100 of the present invention, the contact lens 110 may include at least three lens layers. This prevents colorant from leaking out of the contact lens 110 and reduces the chance of chemical substances coming into contact with the eyes.

In the contact lens product 100 of the present invention, the contact lens product 100 is a one-day disposable product, and the contact lens product 100 may further include a light-proof packaging. Specifically, curcumin derivatives may lose their luminous effect over time after being exposed to light. Therefore, they need to be used within the period when curcumin derivatives have maximum activity to maintain the best light-shielding or light-reducing effect and completely The light-proof packaging blocks light and can protect and maintain the curcumin derivatives in the contact lens 110, helping to preserve it for a long time and maintain the best light-blocking or light-reducing effect.

The contact lens product 100 of the present invention is prepared by the following steps: (1) Synthesize modified curcumin from unmodified curcumin through specific synthesis steps. (2) Add modified curcumin to the specific formula monomer and mix evenly. (3) Homogenize the monomer mixture and then cure it with UV/heat to form the contact lens 110 . (4) The finished contact lens 110 will be processed in a hydration step and stored in the buffer solution 120 . (5) High-temperature sterilize the sealed package containing the contact lens 110 and the buffer solution 120 at 121°C for at least 20 minutes to obtain the contact lens product 100 of the present invention.

In the contact lens product 100 of the present invention, the steps for measuring the transmittance of the contact lens 110 in a specific wavelength range are as follows: (1) Equilibrate the contact lens 110 in the standard solution. (2) Place the contact lens 110 together with the standard solution in a quartz plate, and measure the penetration rate of the contact lens 110 with an instrument under the conditions of a scanning accuracy of 1 nm and a scanning range of 200 nm~800 nm.

Each of the technical features of the above-mentioned contact lens product of the present invention can be combined and configured to achieve corresponding effects.

The functions of the contact lens in the present invention can be myopia correction, hyperopia correction, presbyopia correction, astigmatism correction, myopia control and corneal reshaping. )wait.

The diopter (Diopter) of the contact lens in the present invention is expressed by the D value. For example, the center diopter of the lens for correcting myopia is a negative value, and the center diopter of the lens for correcting hyperopia is a positive value. The aggravation of myopia in the present invention means that the degree of myopia is deepening, and the greater the absolute value of negative refractive power is, for example, -0.5 D is aggravated/deepened to -2.0 D.

The surface shape of the contact lens described in the present invention may vary, such as spherical, plane or aspheric, based on the curved surface shape viewed through the center. The front surface of the contact lens in the present invention refers to the surface away from the cornea of the eyeball, and the back surface (Back surface) refers to the surface close to the cornea of the eyeball.

The stable structure of the contact lens described in the present invention may have a rotationally stable design, such as a thickened vertical weight design at the bottom, a balance design with thickening on both sides, an asymmetric balance design, and an upper and lower thinning stability design.

The structural composition of the contact lenses in the present invention can be at least two layers of lenses; the colored contact lenses can be composed of two layers, such as the lens body layer and the color layer; the color contact lenses can be composed of three layers, such as the lens body layer, the color layer layer and anti-falling protective layer; colored contact lenses can be composed of four layers, such as the lens body layer, the first color layer, the second color layer and the anti-falling protective layer. Colored contact lenses can be composed of five layers, such as the lens body layer, the first color layer, the second color layer, the third color layer and the anti-shedding protective layer. Colored contact lenses can be composed of another five layers, such as the lens body layer, the first color layer, the separation layer, the second color layer and the anti-shedding protective layer.

The composition of the contact lens described in the present invention contains at least two monomers, at least one cross-linking agent, at least one diluent, at least one initiator, and optionally a UV light absorber or a blue light absorber. In this way, the type and content of each component in the composition can be selected and adjusted, which helps to adjust the elastic coefficient of the contact lens and affect the softness and hardness of the contact lens, thereby improving durability and stability, and regulating the most appropriate contact lens. Glasses contain water to increase comfort and oxygen permeability. The composition may contain at least four monomers, at least two cross-linking agents, at least two diluents, at least one initiator, and optionally a UV light absorber or a blue light absorber. In this way, a contact lens containing both the first material and the second material can be prepared.

The hydrogel monomer of the contact lens in the present invention may include: hydroxyethyl methacrylate (HEMA; 2-Hydroxyethyl methacrylate), methacrylic acid (MAA; Methacrylic Acid), 2-methyl-2-acrylic acid-2 , 3-dihydroxypropyl ester (GMA; Glycerol monomethacrylate), N-vinyl-2-pyrrolidone (NVP; N-Vinyl-2-pyrrolidinone), methyl methacrylate (MMA; Methyl methacrylate), N,N -Dimethylacrylamide (DMAA; N,N-Dimethyl Acrylamide), etc. This helps to maintain a moist, smooth, soft and comfortable feeling, allowing it to be worn for a long time and avoid foreign body sensation when wearing it.

The hydrocolloid of the contact lens in the present invention may be, but is not limited to, a contact lens material classified as Group 1 by the US Food and Drug Administration, that is, a nonionic polymer with a low water content (less than 50% by weight). polymer), such as Helfilcon A&B, Hioxifilcon B, Mafilcon, Polymacon, Tefilcon, Tetrafilcon A, etc. Alternatively, the aforementioned hydrocolloid can be a contact lens material classified as Group 2 by the US Food and Drug Administration, that is, a non-ionic polymer with a high water content (greater than 50 weight percent), such as Acofilcon A, Alfafilcon A, Hilafilcon B , Hioxifilcon A, Hioxifilcon B, Hioxifilcon D, Nelfilcon A, Nesofilcon A, Omafilcon A and Samfilcon A, etc. Alternatively, the aforementioned hydrocolloid may be a contact lens material classified as Group 3 by the US Food and Drug Administration, that is, an ionic polymer with low water content (less than 50% by weight), such as Deltafilcon A, etc. Alternatively, the aforementioned hydrocolloid can be a Group 4 contact lens material classified by the US Food and Drug Administration, that is, an ionic polymer with a high water content (greater than 50 weight percent), such as Etafilcon A, Focofilcon A, Methafilcon A, Methafilcon B, Ocufilcon A, Ocufilcon B, Ocufilcon C, Ocufilcon D, Ocufilcon E, Phemfilcon A, Vifilcon A, etc.

The silicone hydrogel monomer of the contact lens in the present invention can be, but is not limited to, 2-hydroxyethyl methacrylate, 2-methyl-2-acrylate-2,3-dihydroxypropyl (glycerol). monomethacrylate), methacrylic acid, methacryloyloxypropyltris(trimethylsilyloxy)silane (3-methacryloyloxypropyltris(trimethylsilyloxy) silane), N-vinyl-2-pyrrolidone (N -vinyl-2-pyrrolidinone), N,N-dimethyl acrylamide (N,N-dimethyl acrylamide), (3-methacryloxy-2-hydroxypropoxy)propylbis(trimethyl) 3-(3-methacryloxy-2-hydroxypropoxy)propylbis(trimethylsiloxy)methylsilane) or 3-acetyloxy-2-hydroxypropoxypropyl-terminated polydimethylsiloxane ((3-acryloxy-2-hydroxypropoxypropyl) terminated polydimethylsiloxane). In this way, the most appropriate monomer type can be selected, which helps to achieve a balanced configuration among the durability, stability, comfort, oxygen permeability and other parameters of the designed contact lens, which can effectively increase the oxygen permeability and avoid corneal defects. Reduce eye bloodshotness, redness and swelling caused by oxygen to provide long-term wearing comfort.

The silicone hydrogel of the contact lenses described in the present invention can be, but is not limited to, contact lens materials classified as Group 5 by the United States Food and Drug Administration (USFDA), such as Balafilcon A, Comfilcon A, Efrofilcon A, Enfilcon A, Galyfilcon A. Lotrafilcon A, Lotrafilcon B, Narafilcon A, Narafilcon B, Senofilcon A, Delefilcon A, Somofilcon A, etc.

The contact lens product described in the present invention can be composed of a contact lens body, a solution and a package. The contact lens body or solution can include: monomer, UV absorber, blue absorber, Beneficial agents, wetting agents, dyes, myopia control agents, salts of weak acids and their conjugate bases, weak bases and their Salts of conjugate acid (Base and its conjugate acid), anionic agent (Anionic agent), cationic agent (Cationic agent) and other auxiliary agents; the packaging of the present invention can be made of a plastic container and an aluminum foil upper cover, and the plastic container can be made of polypropylene (PP; Polypropylene), polystyrene (PS; Polystyrene), polyethylene terephthalate (PET; Polyethylene terephthalate) or other plastic materials. It can also be made of biodegradable plastic (Biodegradable plastic), such as PLA (Polylactic Acid), PHA (polyhydroxyalkanoates) or other degradable plastics, etc. Biodegradable plastics can also be mixed with biodegradable plasticizers (Biodegradable plasticizer) to achieve modification or modification effects; the aluminum foil upper cover of the present invention can be used as a tool Plastic coated composite aluminum foil material.

The initiating agent of the contact lens in the present invention may be, but is not limited to, 2-hydroxy-2-methyl-1-phenyl-1-propone (2-hydroxy-2-methyl-propiophenone). Thereby, the composition of the contact lens can effectively achieve a high-efficiency polymerization reaction.

The cross-linking agent of the contact lens in the present invention may be, but is not limited to, ethylene glycol dimethacrylate or 1,1,1-trimethylol propane trimethacrylate. ). This can effectively achieve good cross-linking effects between monomers and improve the stability and durability of contact lenses.

The diluent of the contact lens in the present invention may be polyethylene glycol 300, polyethylene glycol 600, polyethylene glycol 800, or polyethylene glycol 1000. (polyethylene glycol 1000), polyethylene glycol 2000 (polyethylene glycol 2000), polyethylene glycol 4000 (polyethylene glycol 4000), 1,4-butanediol (1,4-butanediol), ethanol (ethanol), isopropyl Alcohol (isopropyl alcohol), glycerol (glycerol) or n-hexanol (1-hexanol). This can assist in adjusting the elastic coefficient of the contact lens to improve the comfort of wearing the contact lens.

The ultraviolet (UV) absorber of the contact lens in the present invention can be but is not limited to 2-[3-(2H-benzotriazol-2-yl)-4-hydroxyphenyl]ethyl 2- Methacrylate (2-[3-(2H-benzotriazol-2-yl)-4-hydroxyphenyl]ethyl methacrylate), 4-methacryloxy-2-hydroxybenzophenone (4-methacryloxy-2- hydroxybenzophenone), 2-phenylethyl acrylate, 2-phenylethyl methacrylate, 2-[2-hydroxy-5-[2-(methacrylate) Oxy)ethyl]phenyl]-2H-benzotriazole (2-(2'-hydroxy-5'-methacryloxyethylphenyl)-2H-benzotriazole) or 2-acrylic acid 2-(4-benzoyl-3-hydroxy Phenoxy)ethyl ester (2-(4-benzoyl-3-hydroxyphenoxy) ethyl acrylate). In this way, contact lenses can absorb high-energy UV light, thereby reducing the chance of retinal damage by UV light.

The blue light absorber of the contact lens in the present invention may be, but is not limited to, tetraphenyldimethacrylate (4-(phenyldiazenyl) phenyl methacrylate). In this way, contact lenses can absorb high-energy blue light, thereby reducing the chance of retinal damage from blue light.

The wetting agent of the contact lens in the present invention may include: 2-Methacryloyloxyethylphosphorylcholine (MPC; 2-Methacryloyloxyphosphorylcholine), hyaluronic acid (Hyaluronic Acid), alginic acid (Alginic acid) or its salts, etc. .

The pigments of the contact lenses described in the present invention may include: Anthocyanidin, Beta-Carotene, Curcumin, Luciferin, Lutein, Solanum Lycopene, Phycobillin, Phycoerythrim, Phycocyanin, Vitamin B2, Zeaxanthin, Photochromic dyes, Thermochromic dyes, etc., and their derivatives.

The auxiliary agent of the contact lens in the present invention may include: antibiotics, bacteriostatic agents, antiviral agents, antifungal drugs, and antiallergic agents. , Apomorphine, Bromocriptine, Dopamine receptor agonist (Dopamine), Levodopa, or Quinpirole, Steroid, non-steroidal anti-inflammatory agent (NSAIDs), Surfactants, Miotics, Enzyme Inhibitor, Anaesthetic, Vasoconstrictor, Vitamin, Antioxidant, Nutrient wait.

The antioxidants of the contact lenses described in the present invention can be vitamin A (Vitamin A), vitamin C (Vitamin C), vitamin E (Vitamin E), uric acid (Uric acid), carotenoids (Carotenoid), flavonoid compounds ( Flavonoids), Resveratrol, Selenomethionine, etc.

The myopia control agent of the contact lens in the present invention may include: cycloplegic agent, mydriasis agent (mydriatic agent), selective/non-selective muscarinic receptor antagonist, etc., and has the functions of controlling, slowing down, The effect of delaying or preventing the progression of myopia can be achieved, for example, by blocking the M-type muscarinic receptors of the parasympathetic nerve, which relaxes and paralyzes the ciliary muscles that control the pupil, thereby dilating the pupil. Such as Atropine (3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yltropate), Atropine sulphate, Cyclopentolate; 2-(Dimethylamino )ethyl(1-hydroxycyclopentyl)(phenyl)acetate), Cyclopentolate HCl, Eucatropine(1,2,2,6-Tetramethyl-4-piperidinylhydroxy(phenyl)acetate), Homatropine (3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-ylhydroxy(phenyl)acetate), Nuvenzepine, Phenylephrine HCl), Pirenzepine, Raceanisodamine, Rispenzepine, Scopolamine; (1R, 2R, 4S, 5S, 7s)-9-Methyl-3- oxa-9-azatricyclo[3.3.1.02,4]non-7-yl(2S)-3-hydroxy-2-phenylpropanoate), Scopolamine HBr, Telenzepine and Tropical Tropicamide (Tropicamide; N-Ethyl-3-hydroxy-2-phenyl-N-(4-pyridinylmethyl)propanamide), etc., and its salts.

Each of the technical features of the above-mentioned contact lens product of the present invention can be combined and configured to achieve corresponding effects.

Based on the above implementations, specific examples are provided below and described in detail with reference to the drawings.

<1st Embodiment to 4th Embodiment>

In the contact lens products of the first to fourth embodiments, the curcumin derivative of the contact lens has a structure shown in formula (1), and regarding the curcumin derivatives of the first to fourth embodiments Please see Table 1 for details. Table I Curcumin derivatives Curcumin+HEMA*1 structure Formula 1) SMILES logo COC1=C(O)C=CC(\C=C\C(=O)C=C(OCCOC(=O)C(C)=C)\C=C\C2=CC(OC)=C( O)C=C2)=C1 Molecular formula C ₂₇ H ₂₈ O ₈ Molecular weight Wmc (g/mol, Dalton) 480

In the contact lens products of the first to fourth embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agent is hyaluronic acid (HA) and sodium alginate (SA). As for the first Please refer to Table 2 for the values of Ccu, Cao, Cad and Ccu/Cao from the embodiment to the fourth embodiment. Table II 1st Embodiment Second embodiment 3rd embodiment 4th embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 Cad (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<Fifth Embodiment to Eighth Embodiment>

In the contact lens products of the fifth to eighth embodiments, the curcumin derivative of the contact lens has a structure shown in formula (2), and regarding the curcumin derivatives of the fifth to eighth embodiments Please see Table 3 for details. Table 3 Curcumin derivatives Curcumin+HEMA*1 structure Formula (2) SMILES logo COC1=C(O)C=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(OCCOC(=O)C(C)=C )C=C2)=C1 Molecular formula C ₂₇ H ₂₈ O ₈ Molecular weight Wmc (g/mol, Dalton) 480

In the contact lens products of the fifth to eighth embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. As for the Ccu, Cao, Please refer to Table 4 for the values of Cad and Ccu/Cao. Table 4 5th embodiment 6th embodiment 7th Embodiment 8th embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 Cad(%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

Please refer to Figures 2 to 6. Figure 2 shows the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at wavelengths of 280 nm ~ 310 nm. Figure 3 shows the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention. Figure 4 shows the transmittance data of the fifth embodiment, the seventh embodiment of the present invention and the first control group at wavelengths of 310 nm to 380 nm. The fourth figure shows the fifth embodiment, the seventh embodiment of the present invention and the first control group. The transmittance data graph of the first control group at wavelengths 410 nm~460 nm. The fifth graph shows the penetration data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at wavelengths 460 nm~780 nm. The transmittance data graph of the fifth embodiment, the seventh embodiment and the first control group of the present invention is shown in Figure 6 at wavelengths of 380 nm to 780 nm. In addition, in order to more clearly demonstrate the effect of adding antioxidants to the buffer solution of the contact lens product of the present invention to overcome the destruction of the stability of curcumin derivatives due to high-temperature and high-pressure sterilization, a first control group that does not contain antioxidants is further proposed. , for comparison with the fifth embodiment and the seventh embodiment, in which the curcumin derivative of the first control group has a structure shown in formula (2), and Ccu = 0.05%.

The T2831, T3138, T4146, T4678, and T3878 of the 1st control group, the 5th embodiment, and the 7th embodiment were treated one day before sterilization (Day -1), on the day of sterilization (Day 0), and ten days after sterilization. The value of day (10th day) is recorded in Table 5. Table 5 1st control group 5th embodiment 7th Embodiment Antioxidants 0% Vitamin C 0.10% Vitamin C 1.00% Sterilization period (days) -1 0 10 -1 0 10 -1 0 10 T2831 93.2 87.7 92.6 90.4 87.4 86.8 93.4 16.7 75.4 T3138 93.0 94.9 95.0 90.6 90.7 91.4 93.1 76.9 81.5 T4146 92.5 96.2 97.3 90.7 94.2 95.7 92.8 90.8 89.1 T4678 99.0 99.3 99.1 98.7 98.9 98.2 98.8 99.0 97.5 T3878 97.7 98.7 98.7 97.1 97.8 97.6 97.5 97.1 95.5

In addition, here we further calculate the sterilization process of the fifth and seventh embodiments based on the T2831, T3138, T4146, T4678, and T3878 values of the first control group and the fifth embodiment and the first control group and the seventh embodiment. The values of BE2831, BE3138, BE4146, BE4678 and BE3878 on the same day and ten days after sterilization. In detail, the absorption blocking efficiency referred to in this specification is the average penetration in a specific wavelength range of a contact lens product containing curcumin derivatives (C) and a contact lens product that generally does not contain curcumin derivatives (nC) Rate difference percentage. For example, taking the average transmittance T2831 of a contact lens at a wavelength of 280 nm to 310 nm on the 10th day after sterilization as an example, the method of calculating its absorption blocking efficiency BE2831 at a wavelength of 280 nm to 310 nm is as follows: BE2831 = ( |(C _T2831 – nC _T2831 )|/nC _T2831 ) × 100, where C _T2831 is the value of the average transmittance T2831 of contact lens products containing curcumin derivatives at wavelengths 280 nm ~ 310 nm, and nC _T2831 is The average transmittance T2831 of contact lens products that generally do not contain curcumin derivatives at wavelengths of 280 nm ~ 310 nm. The BE2831, BE3138, BE4146, BE4678, and BE3878 values of the first control group and the fifth embodiment and the first control group and the seventh embodiment are recorded in Table 6. Table 6 1st Control Group and 5th Example 1st Control Group and 7th Example Sterilization period (days) 0 10 0 10 BE2831 0.3 6.2 81.0 18.6 BE3138 4.4 3.8 19.0 14.2 BE4146 2.1 1.6 5.6 8.4 BE4678 0.4 0.9 0.4 1.7 BE3878 0.8 1.1 1.6 3.2

Please refer to Figures 7 to 11. Figure 7 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at a wavelength of 280 nm~310 nm. Figure 8 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group. The transmittance data graph of the eighth embodiment and the second control group at the wavelength of 310 nm~380 nm. The ninth graph shows the transmittance of the eighth embodiment of the present invention and the second control group at the wavelength of 410 nm~460 nm. Data graph, Figure 10 shows the transmittance data graph of the eighth embodiment of the present invention and the second control group at a wavelength of 460 nm~780 nm, and Figure 11 illustrates the eighth embodiment of the present invention and the second control group. Transmittance data chart of the control group at wavelengths 380 nm~780 nm. In addition, in order to more clearly demonstrate the effect of adding antioxidants to the buffer solution of the contact lens product of the present invention to overcome the destruction of the stability of curcumin derivatives due to high-temperature and high-pressure sterilization, a second control group that does not contain antioxidants is further proposed. , for comparison with the eighth embodiment, in which the curcumin derivative of the second control group has a structure shown in formula (2), and Ccu = 0.05%.

The second control group and T2831, T3138, T4146, T4678, and T3878 of the eighth embodiment were treated one day before sterilization (day -1), on the day of sterilization (day 0), and ten days after sterilization (day 10). ) and the values seventeen days after sterilization (day 17) are recorded in Table 7. Table 7 2nd control group 8th embodiment Antioxidants 0% Vitamin C 1.00% Sterilization period (days) -1 0 10 17 -1 0 10 17 T2831 87.6 84.2 85.6 88.3 87.0 22.1 72.4 51.4 T3138 84.2 90.8 91.2 92.1 83.6 73.1 76.1 60.8 T4146 77.7 95.1 96.4 96.8 76.6 77.5 80.3 74.0 T4678 98.3 99.3 99.0 98.9 98.0 97.9 97.2 94.4 T3878 94.3 98.3 98.4 98.4 93.8 93.7 93.6 89.8

In addition, based on the T2831, T3138, T4146, T4678, and T3878 values of the second control group and the eighth embodiment, the calculation results of the eighth embodiment on the day of sterilization, ten days after the sterilization, and seventeen days after the sterilization are further calculated. Values of BE2831, BE3138, BE4146, BE4678, BE3878 for the day. The values of BE2831, BE3138, BE4146, BE4678, and BE3878 of the second control group and the eighth embodiment are recorded in Table 8. Table 8 2nd control group and 8th embodiment Sterilization period (days) 0 10 17 BE2831 73.7 15.4 41.7 BE3138 19.5 16.6 33.9 BE4146 18.5 16.7 23.6 BE4678 1.4 1.9 4.6 BE3878 4.7 4.9 8.8

<9th Embodiment to 12th Embodiment>

In the contact lens products of the 9th to 12th embodiments, the curcumin derivative of the contact lens has a structure shown in formula (3), and regarding the curcumin derivatives of the 9th to 12th embodiments Please see Table 9 for details. Table 9 Curcumin derivatives Curcumin+HEMA*2 structure Formula (3) SMILES logo COC1=C(OCCOC(=O)C(C)=C)C=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(OCCOC (=O)C(C)=C)C=C2)=C1 Molecular formula C ₃₃ H ₃₆ O ₁₀ Molecular weight Wmc (g/mol, Dalton) 592

In the contact lens products of the ninth to twelfth embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. As for the Ccu, Cao, Please refer to Table 10 for the values of Cad and Ccu/Cao. Table 10 9th Embodiment 10th embodiment 11th Embodiment 12th embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 Cad(%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<Thirteenth Embodiment to Sixteenth Embodiment>

In the contact lens products of the 13th to 16th embodiments, the curcumin derivative of the contact lens has a structure shown in formula (4), and regarding the curcumin derivatives of the 13th to 16th embodiments Please see Table 11 for details. Table 11 Curcumin derivatives Curcumin+HEMA*2 structure Formula (4) SMILES logo COC1=C(O)C=CC(\C=C\C(OCCOC(=O)C(C)=C)=CC(=O)\C=C\C2=CC(OC)=C(OCCOC (=O)C(C)=C)C=C2)=C1 Molecular formula C ₃₃ H ₃₆ O ₁₀ Molecular weight Wmc (g/mol, Dalton) 592

In the contact lens products of the 13th to 16th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. As for the Ccu, Cao, Please refer to Table 12 for the values of Cad and Ccu/Cao. Table 12 13th embodiment 14th embodiment Embodiment 15 16th embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 Cad (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<17th Embodiment to 20th Embodiment>

In the contact lens products of the 17th to 20th embodiments, the curcumin derivative of the contact lens has a structure shown in formula (5), and regarding the curcumin derivatives of the 17th to 20th embodiments Please see Table 13 for details. Table 13 Curcumin derivatives Curcumin+HEMA*3 structure Formula (5) SMILES logo COC1=C(OCCOC(=O)C(C)=C)C=CC(\C=C\C(=O)C=C(OCCOC(=O)C(C)=C)\C=C \C2=CC(OC)=C(OCCOC(=O)C(C)=C)C=C2)=C1 Molecular formula C ₃₉ H ₄₄ O ₁₂ Molecular weight Wmc (g/mol, Dalton) 704

In the contact lens products of the 17th to 20th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. As for the Ccu, Cao, Please refer to Table 14 for the values of Cad and Ccu/Cao. Table 14 Seventeenth Embodiment 18th Embodiment 19th Embodiment 20th embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 Cad(%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<21st Embodiment to 24th Embodiment>

In the contact lens products of the 21st to 24th embodiments, the curcumin derivative of the contact lens has a structure shown in formula (6), and regarding the curcumin derivatives of the 21st to 24th embodiments Please see Table 15 for details. Table 15 Curcumin derivatives Curcumin+MAA*1 structure Formula (6) SMILES logo COC1=C(O)C=CC(\C=C\C(O)=CC(=O)\C=C\C2=CC(OC)=C(OC(=O)C(C)=C )C=C2)=C1 Molecular formula C ₂₅ H ₂₄ O ₇ Molecular weight Wmc (g/mol, Dalton) 436

In the contact lens products of the 21st to 24th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. As for the Ccu, Cao, Please refer to Table 16 for the values of Cad and Ccu/Cao. Table 16 21st Embodiment 22nd Embodiment 23rd embodiment 24th Embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 Cad (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<25th Embodiment to 28th Embodiment>

In the contact lens products of the 25th embodiment to the 28th embodiment, the curcumin derivative of the contact lens has a structure shown in formula (7), and regarding the curcumin derivatives of the 25th embodiment to the 28th embodiment Please see Table 17 for details. Table 17 Curcumin derivatives Curcumin+MAA*1 structure Formula (7) SMILES logo COC1=C(O)C=CC(\C=C\C(=O)C=C(OC(=O)C(C)=C)\C=C\C2=CC(OC)=C( O)C=C2)=C1 Molecular formula C ₂₅ H ₂₄ O ₇ Molecular weight Wmc (g/mol, Dalton) 436

In the contact lens products of the 25th to 28th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. As for the Ccu, Cao, Please refer to Table 18 for the values of Cad and Ccu/Cao. Table 18 25th embodiment 26th Embodiment 27th Embodiment 28th Embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 Cad(%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<29th Embodiment to 32nd Embodiment>

In the contact lens products of the 29th to 32nd embodiments, the curcumin derivative of the contact lens has a structure shown in formula (8), and regarding the curcumin derivatives of the 29th to 32nd embodiments Please see Table 19 for details. Table 19 Curcumin derivatives Curcumin+MAA*2 structure Formula (8) SMILES logo COC1=C(OC(=O)C(C)=C)C=CC(\C=C\C(O)=CC(=O)\C=C\C2=CC(OC)=C(OC (=O)C(C)=C)C=C2)=C1 Molecular formula C ₂₉ H ₂₈ O ₈ Molecular weight Wmc (g/mol, Dalton) 504

In the contact lens products of the 29th to 32nd embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. As for the Ccu, Cao, Please refer to Table 20 for the values of Cad and Ccu/Cao. Table 20 29th Embodiment 30th Embodiment 31st Embodiment 32nd Embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 Cad (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<33rd Embodiment to 36th Embodiment>

In the contact lens products of the 33rd to 36th embodiments, the curcumin derivative of the contact lens has a structure shown in formula (9), and regarding the curcumin derivatives of the 33rd to 36th embodiments Please see Table 21 for details. Table 21 Curcumin derivatives Curcumin+MAA*2 structure Formula (9) SMILES logo COC1=C(O)C=CC(\C=C\C(OC(=O)C(C)=C)=CC(=O)\C=C\C2=CC(OC)=C(OC (=O)C(C)=C)C=C2)=C1 Molecular formula C ₂₉ H ₂₈ O ₈ Molecular weight Wmc (g/mol, Dalton) 504

In the contact lens products of the 33rd to 36th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. As for the Ccu, Cao, Please refer to Table 22 for the values of Cad and Ccu/Cao. Table 22 33rd Embodiment 34th Embodiment 35th Embodiment 36th Embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 Cad(%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<37th Embodiment to 40th Embodiment>

In the contact lens products of the 37th to 40th embodiments, the curcumin derivative of the contact lens has a structure shown in formula (10), and regarding the curcumin derivatives of the 37th to 40th embodiments Please see Table 23 for details. Table 23 Curcumin derivatives Curcumin+MAA*3 structure Formula (10) SMILES logo COC1=C(OC(=O)C(C)=C)C=CC(\C=C\C(=O)C=C(OC(=O)C(C)=C)\C=C \C2=CC(OC)=C(OC(=O)C(C)=C)C=C2)=C1 Molecular formula C ₃₃ H ₃₂ O ₉ Molecular weight Wmc (g/mol, Dalton) 572

In the contact lens products of the 37th to 40th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. As for the Ccu, Cao, Please refer to Table 24 for the values of Cad and Ccu/Cao. Table 24 37th Embodiment Embodiment 38 Embodiment 39 40th Embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 Cad(%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<41st Embodiment to 44th Embodiment>

In the contact lens products of the 41st to 44th embodiments, the curcumin derivative of the contact lens has a structure shown in formula (11), and regarding the curcumin derivatives of the 41st to 44th embodiments Please see Table 25 for details. Table 25 Curcumin derivatives Curcumin+GMA*1 structure Formula (11) SMILES logo COC1=C(O)C=CC(\C=C\C(O)=CC(=O)\C=C\C2=CC(OC)=C(OCC(O)COC(=O)C( C)=C)C=C2)=C1 Molecular formula C ₂₈ H ₃₀ O ₉ Molecular weight Wmc (g/mol, Dalton) 510

In the contact lens products of the 41st to 44th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. As for the Ccu, Cao, Please refer to Table 26 for the values of Cad and Ccu/Cao. Table 26 41st Embodiment 42nd Embodiment 43rd Embodiment 44th Embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 Cad (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<45th Embodiment to 48th Embodiment>

In the contact lens products of the 45th embodiment to the 48th embodiment, the curcumin derivative of the contact lens has a structure shown in formula (12), and regarding the curcumin derivatives of the 45th embodiment to the 48th embodiment Please see Table 27 for details. Table 27 Curcumin derivatives Curcumin+GMA*1 structure Formula (12) SMILES logo COC1=C(O)C=CC(\C=C\C(=O)C=C(OCC(O)COC(=O)C(C)=C)\C=C\C2=CC(OC )=C(O)C=C2)=C1 Molecular formula C ₂₈ H ₃₀ O ₉ Molecular weight Wmc (g/mol, Dalton) 510

In the contact lens products of the 45th to 48th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. As for the Ccu, Cao, Please refer to Table 28 for the values of Cad and Ccu/Cao. Table 28 45th Embodiment 46th Embodiment 47th Embodiment 48th Embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 Cad(%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<49th Embodiment to 52nd Embodiment>

In the contact lens products of the 49th embodiment to the 52nd embodiment, the curcumin derivative of the contact lens has a structure shown in formula (13), and regarding the curcumin derivatives of the 49th embodiment to the 52nd embodiment Please see Table 29 for details. Table 29 Curcumin derivatives Curcumin+GMA*2 structure Formula (13) SMILES logo COC1=C(OCC(O)COC(=O)C(C)=C)C=CC(\C=C\C(O)=CC(=O)\C=C\C2=CC(OC) =C(OCC(O)COC(=O)C(C)=C)C=C2)=C1 Molecular formula C ₃₅ H ₄₀ O ₁₂ Molecular weight Wmc (g/mol, Dalton) 652

In the contact lens products of the 49th to 52nd embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. As for the Ccu, Cao, Please refer to Table 30 for the values of Cad and Ccu/Cao. Table 30 Embodiment 49 50th Embodiment 51st Embodiment 52nd Embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 Cad (%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<53rd Embodiment to 56th Embodiment>

In the contact lens products of the 53rd embodiment to the 56th embodiment, the curcumin derivative of the contact lens has a structure shown in formula (14), and regarding the curcumin derivatives of the 53rd embodiment to the 56th embodiment Please see Table 31 for details. Table 31 Curcumin derivatives Curcumin+GMA*2 structure Formula (14) SMILES logo COC1=C(O)C=CC(\C=C\C(OCC(O)COC(=O)C(C)=C)=CC(=O)\C=C\C2=CC(OC) =C(OCC(O)COC(=O)C(C)=C)C=C2)=C1 Molecular formula C ₃₅ H ₄₀ O ₁₂ Molecular weight Wmc (g/mol, Dalton) 652

In the contact lens products of the 53rd to 56th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. As for the Ccu, Cao, Please refer to Table 32 for the values of Cad and Ccu/Cao. Table 32 53rd Embodiment 54th Embodiment 55th Embodiment 56th Embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 Cad(%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

<57th Embodiment to 60th Embodiment>

In the contact lens products of the 57th to 60th embodiments, the curcumin derivative of the contact lens has a structure shown in formula (15), and regarding the curcumin derivatives of the 57th to 60th embodiments Please see Table 33 for details. Table 33 Curcumin derivatives Curcumin+GMA*3 structure Formula (15) SMILES logo COC1=C(OCC(O)COC(=O)C(C)=C)C=CC(\C=C\C(=O)C=C(OCC(O)COC(=O)C(C )=C)\C=C\C2=CC(OC)=C(OCC(O)COC(=O)C(C)=C)C=C2)=C1 Molecular formula C ₄₂ H ₅₀ O ₁₅ Molecular weight Wmc (g/mol, Dalton) 794

In the contact lens products of the 57th to 60th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. As for the Ccu, Cao, Please refer to Table 34 for the values of Cad and Ccu/Cao. Table 34 57th Embodiment 58th Embodiment Embodiment 59 60th Embodiment Ccu (%) 0.05 0.50 0.05 0.50 Cao (%) 0.10 0.10 1.00 1.00 Cad(%) HA 0.01 0.01 0.03 0.06 SA 0.01 0.01 0.05 0.06 Ccu/Cao 0.50 5.00 0.05 0.50

Although the present invention has been disclosed in the above embodiments, it is not intended to limit the present invention. Anyone skilled in the art can make various modifications and modifications without departing from the spirit and scope of the present invention. Therefore, the protection of the present invention is The scope shall be determined by the appended patent application scope.

100:Contact lens products 110:Contact Lenses 120: Buffer solution

In order to make the above and other objects, features, advantages and embodiments of the present invention more apparent and understandable, the accompanying drawings are described as follows: Figure 1 is a schematic diagram of a contact lens product according to an embodiment of the present invention; Figure 2 shows the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at wavelengths of 280 nm~310 nm; Figure 3 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at wavelengths of 310 nm~380 nm; Figure 4 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at wavelengths of 410 nm~460 nm; Figure 5 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at wavelengths of 460 nm~780 nm; Figure 6 shows the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at wavelengths of 380 nm~780 nm; Figure 7 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at wavelengths of 280 nm~310 nm; Figure 8 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at wavelengths of 310 nm to 380 nm; Figure 9 shows the transmittance data of the eighth embodiment of the present invention and the second control group at wavelengths of 410 nm~460 nm; Figure 10 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at wavelengths of 460 nm~780 nm; and Figure 11 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at wavelengths of 380 nm to 780 nm.

100:Contact lens products

110:Contact Lenses

120: Buffer solution

Claims (12)

A contact lens product, comprising: a contact lens; and a buffer solution, the contact lens is stored in the buffer solution, wherein the buffer solution contains at least one antioxidant; wherein the contact lens contains at least one curcumin derivative, the Curcumin derivatives have a structure shown in formula (I) or formula (II): Formula (I), wherein R ₁ and R ₂ are not both hydrogen; or Formula (II), Wherein R ₅ is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid and 2-methyl-2-acrylic acid-2,3-dihydroxypropyl ester, and R ₃ and R ₄ are not hydrogen at the same time. ; Wherein, the weight percent concentration of the curcumin derivative in the contact lens is Ccu, and the weight percent concentration of the antioxidant in the buffer solution is Cao, which meets the following conditions: 0.01% ≤ Ccu ≤ 5.00%; and 0.05 % ≤ Cao ≤ 5.00%. The contact lens product as described in claim 1, wherein the weight percent concentration of the curcumin derivative in the contact lens is Ccu, which meets the following conditions: 0.03% ≤ Ccu ≤ 3.00%. The contact lens product as described in claim 2, wherein the weight percent concentration of the curcumin derivative in the contact lens is Ccu, which meets the following conditions: 0.04% ≤ Ccu ≤ 1.00%. The contact lens product as described in claim 1, wherein the weight percent concentration of the antioxidant in the buffer solution is Cao, which satisfies the following conditions: 0.07% ≤ Cao ≤ 3.00%. The contact lens product as described in claim 4, wherein the weight percent concentration of the antioxidant in the buffer solution is Cao, which meets the following conditions: 0.09% ≤ Cao ≤ 1.50%. The contact lens product as described in claim 1, wherein the weight percent concentration of the curcumin derivative in the contact lens is Ccu, and the weight percent concentration of the antioxidant in the buffer solution is Cao, which satisfies the following conditions: 0.01 ≤ Ccu/Cao ≤ 10.00. The contact lens product as described in claim 6, wherein the molecular weight of the curcumin derivative is Wmc, which meets the following conditions: 450 ≤ Wmc ≤ 750. The contact lens product as described in claim 7, wherein the average transmittance of the contact lens at a wavelength of 280 nm~310 nm is T2831 at least one day after the contact lens is sterilized, which meets the following conditions: 50% ≤ T2831 ≤ 90%. The contact lens product as described in claim 8, wherein the average transmittance of the contact lens at wavelengths 310 nm to 380 nm is T3138 at least one day after the contact lens is sterilized, which meets the following conditions: 60% ≤ T3138 ≤ 92%. The contact lens product as claimed in claim 1, wherein the contact lens further contains at least one myopia control agent. The contact lens product as claimed in claim 1, wherein the contact lens further contains at least one auxiliary agent. The contact lens product as claimed in claim 1, wherein a package of the contact lens product contains biodegradable plastic.

Images